| Income Statement | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| (loss)/profit before income tax expense | -29,728 | -47,009 | -16,786 | 70,047 |
| Income tax expense | 612 | 575 | 831 | 526 |
| Net (loss)/profit attributable to ordinary shareholders | -30,340 | -47,584 | -17,617 | 69,521 |
| Earnings per share, basic | -0.02 | -0.03 | -0.01 | 0.05 |
| Earnings per share, diluted | -0.02 | -0.03 | -0.01 | 0.04 |
| Weighted average shares outstanding, basic | 1,584,522,868 | 1,542,159,622 | 1,534,613,977 | 1,533,531,837 |
| Weighted average shares outstanding, diluted | 1,584,522,868 | 1,542,159,622 | 1,534,613,977 | 1,559,183,774 |
Adaptimmune Therapeutics PLC (ADAP)
Adaptimmune Therapeutics PLC (ADAP)